In Conversation

Sampada Gosavi – General Manager & Managing Director India, Astellas Pharma

Sampada Gosavi – General Manager & Managing Director India, Astellas Pharma

Over the next three years, our focus is set on three fundamental elements to drive growth and impact: portfolio transformation, capability building, and expanding the HCP network
Monica Bettencourt-Dias – Principal Investigator & Former Director, Gulbenkian Institute for Science (IGC)

Monica Bettencourt-Dias – Principal Investigator & Former Director, Gulbenkian Institute for Science (IGC)

The funding landscape for science in Portugal is facing challenges that stem from a decrease in overall investment and shifting priorities. Despite the evident role of blue-sky research, exemplified by important contributions to critical advancements like RNA vaccines, there has not been a corresponding increase in funding
Agata Jakoncic – Managing Director, MSD Greece, Cyprus & Malta

Agata Jakoncic – Managing Director, MSD Greece, Cyprus & Malta

The way our system has developed means that either we all win together, or we all lose together. Collaboration, therefore, is the key to future success
Albert Wong – CEO, Hong Kong Science and Technology Parks Corporation

Albert Wong – CEO, Hong Kong Science and Technology Parks Corporation

We are open for business and want to bring the best people, best companies, and best investors into Hong Kong
Glen Godresse – Chief Marketing Officer & Head of Commercial Excellence, Menarini Asia-Pacific

Glen Godresse – Chief Marketing Officer & Head of Commercial Excellence, Menarini Asia-Pacific

We are extremely proud of our ability to ‘turn rocks into diamonds’, which in essence is commercial excellence in action
Mohamed El Bouhmadi – President & CEO, Zenith Pharma

Mohamed El Bouhmadi – President & CEO, Zenith Pharma

We need a balanced approach that would allow for reasonable medication prices while ensuring the long-term sustainability of the social security system
Flavio Devoto – VP Latin America, AbbVie

Flavio Devoto – VP Latin America, AbbVie

Our view is that all stakeholders – not just payers – have responsibility for ensuring access, meaning that building on strong collaborations and public-private partnerships will be crucial
Jorge A. Guzman – CEO, Cleveland Clinic Abu Dhabi

Jorge A. Guzman – CEO, Cleveland Clinic Abu Dhabi

The UAE has the right ecosystem; it is one of the few places in the world that is positioned to leapfrog significantly in healthcare
See more

In Case You Missed It

InFigures

Belgium, with a total of EUR 5.5 billion in R&D spending in 2021, is the country with the fourth largest research expenditure in the EU and the first per inhabitant.  As a recent study from Deloitte sponsored by the Belgian pharmaceutical industry association, pharma.be, shows, Belgium is also a leader in clinical trials, maintaining its…

The subject of intense industry criticism from the likes of lobby groups, Big Pharma, and biotech alike, the Inflation Reduction Act (IRA) subjects certain drugs to price negotiations directly with industry sponsors in the US for the first time. Ten initial drugs – which accounted for over USD 45 billion in Medicare Part D spending…

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here